Yuan Fengyan, Yang Yiyuan, Zhou Huiqin, Quan Jing, Liu Chongyang, Wang Yi, Zhang Yujing, Yu Xing
Key Laboratory of Model Animals and Stem Cell Biology of Hunan Province, School of Medicine, Hunan Normal University, Changsha, China.
Front Chem. 2022 Sep 9;10:926353. doi: 10.3389/fchem.2022.926353. eCollection 2022.
Heparanase, a member of the carbohydrate-active enzyme (CAZy) GH79 family, is an endo-β-glucuronidase capable of degrading the carbohydrate moiety of heparan sulphate proteoglycans, thus modulating and facilitating remodeling of the extracellular matrix. Heparanase activity is strongly associated with major human pathological complications, including but not limited to tumour progress, angiogenesis and inflammation, which make heparanase a valuable therapeutic target. Long-due crystallographic structures of human and bacterial heparanases have been recently determined. Though the overall architecture of human heparanase is generally comparable to that of bacterial glucuronidases, remarkable differences exist in their substrate recognition mode. Better understanding of regulatory mechanisms of heparanase in substrate recognition would provide novel insight into the anti-heparanase inhibitor development as well as potential clinical applications.
乙酰肝素酶是碳水化合物活性酶(CAZy)GH79家族的成员,是一种内切β-葡萄糖醛酸酶,能够降解硫酸乙酰肝素蛋白聚糖的碳水化合物部分,从而调节并促进细胞外基质的重塑。乙酰肝素酶活性与主要的人类病理并发症密切相关,包括但不限于肿瘤进展、血管生成和炎症,这使得乙酰肝素酶成为一个有价值的治疗靶点。最近已确定了人源和细菌源乙酰肝素酶长期以来一直欠缺的晶体结构。虽然人源乙酰肝素酶的整体结构通常与细菌葡萄糖醛酸酶的结构相当,但它们在底物识别模式上存在显著差异。更好地理解乙酰肝素酶在底物识别中的调控机制,将为抗乙酰肝素酶抑制剂的开发以及潜在的临床应用提供新的见解。